alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 39 studies published 2000 · free to read (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Clinical Infectious Diseases 2000-08-01

The of establishing the diagnosis of pneumonia and cause is with the antibiotic studies for of community-acquired studies for of community-acquired The diagnosis of is based on a of clinical and laboratory The diagnosis of is and and as well as disease, congestive heart failure, with pneumonia and cases of and are of do not require and are the of antibiotic antimicrobial is usually for and a chest radiography is usually to establish the diagnosis of examination to or is for detecting pneumonia Chest radiography is considered is for the etiologic the and or conditions. 5 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA 2000-02-01

Estrogen replacement therapy for 1 year did not slow disease progression nor did it improve global, cognitive, or functional outcomes in women with mild to moderate AD. 3 key findings →

Participants: 42 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Lecithin for dementia and cognitive impairment

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The Cochrane database of systematic reviews 2000-01-01

Alzheimer's disease sufferers have been found to have a lack of the enzyme responsible for converting choline into acetylcholine within the brain. 5 key findings →

Design: randomized controlled trial Participants: 265 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

✓ Peer-reviewed alzhub usefulness score 64 out of 100. BMJ (Clinical research ed.) 2000-12-01

As galantamine slowed the decline of functional ability as well as cognition, its effects are likely to be clinically relevant. 1 key finding →

Participants: 653 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Arteriosclerosis, thrombosis, and vascular biology 2000-10-01

Cardiovascular risk factors often cluster into a metabolic syndrome that may increase the risk of dementia. 2 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Patterns of brain activation in people at risk for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The New England journal of medicine 2000-08-01

Both the magnitude and the extent of brain activation during memory-activation tasks in regions affected by Alzheimer's disease, including the left hippocampal, parietal, and prefrontal regions, were greater among the carriers of the APOE epsilon4 allele than among the carriers of the APOE epsilon3 allele. 1 key finding →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Measuring the thickness of the human cerebral cortex from magnetic resonance images

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Proceedings of the National Academy of Sciences 2000-09-12

Accurate and automated methods for measuring the thickness of human cerebral cortex could provide powerful tools for diagnosing and studying a variety of neurodegenerative and psychiatric disorders.

Full summary, score breakdown and related studies → Original source Free full text

Motor impairment in PD: relationship to incident dementia and age

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2000-08-01

Of 173 patients followed for at least 1 year, 50 became demented according to the Diagnostic and Statistical Manual of Mental Disorders, revised 3rd edition (DSM III-R) criteria (mean follow-up, 3.6 +/- 2. 2 years). 5 key findings →

Participants: 173 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of Neuroscience 2000-06-01

Amyloid plaques are a neuropathological hallmark of Alzheimer's disease (AD), but their relationship to neurodegeneration and dementia remains controversial.

Full summary, score breakdown and related studies → Original source Free full text

Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease?

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neurology, neurosurgery, and psychiatry 2000-08-01

Factor analysis showed four robust and meaningful symptom clusters: factor 1-stereotypic and eating behaviour; factor 2-executive dysfunction and self care; factor 3-mood changes; factor 4-loss of social awareness. 4 key findings →

Participants: 33 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The American journal of pathology 2000-07-01

Endocytosis is critical to the function and fate of molecules important to Alzheimer's disease (AD) etiology, including the beta protein precursor (betaPP), amyloid beta (Abeta) peptide, and apolipoprotein E (ApoE). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The number of trait loci in late-onset Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 51 out of 100. American journal of human genetics 2000-01-01

Although it is clear that apoE plays an important role in the genetics of late-onset Alzheimer disease (AD), evidence exists that additional genes may play a role in AD, and estimates of the total contribution of apoE to the variance in onset of AD vary widely. 2 key findings →

Participants: 742 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Nicotine for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Cochrane database of systematic reviews 2000-01-01

Nicotine is a cholinergic agonist that acts, not only post-synaptically, but also releases pre-synaptic acetylcholine, and in animal models has been shown to reverse spatial memory decline in rats with lesion in the medial septal nucleus and to show recovery on memory in aged monkeys. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The British journal of psychiatry : the journal of mental science 2000-09-01

Both scales are useful instruments for the clinical assessment of fluctuation in dementia. 2 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of lipid research 2000-02-01

Alzheimer's disease (AD) is characterized by the presence of senile plaques, neurofibrillary tangles, and neuronal cell loss associated with membrane cholesterol release. 24S-hydroxycholesterol (24S-OH-Chol) is an enzymatically oxidized product of cholesterol mainly synthesized in the brain. 3 key findings →

Participants: 12 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The rise and fall of frequency and imageability: noun and verb production in semantic dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain and language 2000-06-01

This study examines the impact of progressive degeneration of conceptual knowledge on the content words used in connected speech elicited using the Cookie Theft picture description (Goodglass & Kaplan. 1983). 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurology, neurosurgery, and psychiatry 2000-11-01

It has been shown that atrophy of medial temporal lobe structures such as the hippocampus and entorhinal cortex shown on MRI may distinguish patients with Alzheimer's disease from healthy controls. 4 key findings →

Participants: 41 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2000-04-01

Familial Danish dementia (FDD), also known as heredopathia ophthalmo-oto-encephalica, is an autosomal dominant disorder characterized by cataracts, deafness, progressive ataxia, and dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed